<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00231829</url>
  </required_header>
  <id_info>
    <org_study_id>MMC-03-04-084</org_study_id>
    <nct_id>NCT00231829</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers</brief_title>
  <official_title>A Pilot Phase II Trial of Celecoxib in Patients With Grade 2 or 3 Endometrioid-type, Clear Cell, and Papillary Serous Uterine Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mark H. Einstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmacia</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Expression of COX-II has been identified in many types of human cancers. Uterine cancer is
      the most common gynecologic cancer in the US and there has been an increase in uterine cancer
      deaths over the past decade mainly due to the difficulty in treating recurrences in the more
      aggressive histologic types. The study co-investigators have also identified COX-II
      expression in grade 2 and 3 endometrioid-type, clear cell, and papillary serous types of
      uterine cancers. Upregulation of COX-II may control the cell cycle by regulating the
      proliferative capacity of neoplastic endometrial cells. This is a Phase II pre-post
      intervention comparison study in eligible patients looking at the effects of a COX-II
      inhibitor on uterine cancer. The patients whose endometrial biopsy shows grade 2 or 3
      endometrioid-type, clear cell, and papillary serous types of uterine cancers will be put on a
      selective COX-II inhibitor, Celebrex (Celecoxib) until the day of their surgery. We
      hypothesize that Celecoxib will downregulate the expression of COX-II in these tumor types as
      it does in other similar tumors. We also hypothesize that apoptosis, as measured with the
      TUNEL assay, will be increased in areas with less COX-II expression and should be inversely
      proportional to cellular p21 expression. We hypothesize COX-related gene expression will be
      altered thus suggesting an up- or down-regulation of these genes in the end-organ tissue.
      Documenting downregulation of COX-II enzyme and altered gene expression in endometrial
      carcinoma after treatment with Celecoxib may result in further prospective studies using
      selective COX-II inhibitors as effective, well-tolerated chemotherapeutic agents in these
      uterine cancers that are resistant to many current therapies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endometrial cancer is the most common gynecologic cancer in the United States. The number of
      deaths from endometrial cancer has risen 128% since 1987. In 2001, an estimated 38,300 women
      will develop endometrial cancer (ACS Facts and Figures) and an estimated 6,600 women will die
      from endometrial cancer. Preinvasive and well-differentiated endometrial cancers are
      hormonally driven and often cured with surgery alone. Higher-grade tumors are usually not
      hormonally driven and proliferate via unknown mechanisms. These tumors are largely
      responsible for the rising death rate. Responses to toxic treatment protocols for recurrent
      endometrial cancer are dismal. Unfortunately, these post-menopausal women also often have
      comorbidities, which limit their eligibility for current chemotherapy and radiotherapy
      treatments.

      Expression of COX-II has been identified in many human cancers including: colon cancer,
      gastric cancer, esophogeal cancer, bladder cancer, head and neck cancer, liver cancer,
      pancreatic cancer, prostate cancer and breast cancer. COX-II expression is also strongly
      expressed in the primary tumor and metastasic site in human cervical cancer. COX-II may
      influence cell cycle control by upregulating the proliferative capacity of neoplastic
      endometrial cells. Furthermore, COX-II inhibitors inhibit tumor proliferation even in cells
      that do not express COX. This suggests an alternative mechanism of action not yet defined
      that may play a role in inhibiting the growth of cancer tissue.

      The enhanced expression of COX-II has led investigators to use COX-II inhibitors in the
      prevention and/or treatment of colon and prostate cancers both in vivo and in vitro.
      Celecoxib is now FDA approved for chemoprevention of colon cancer in familial adenomatous
      polyposis patients. If it can be shown that COX-II is downregulated by COX-II inhibitors in
      endometrial cancer, they may offer similar chemopreventative or chemotherapeutic potentials
      that have already been proven in colon cancer.

      COX-II enzyme activity may not always correlate with end organ gene expression. Multiple
      genes have been implicated in apoptotic pathways and are affected by COX-II inhibitors.
      NS-398, a selective COX-II inhibitor causes elevations in APC expression and downregulation
      of c-myc. Prostate apoptosis response 4 (Par-4) levels are increased in cells treated with
      COX inhibitors. PTEN and hMLH1 are genes which are implicated in malignant transformation of
      endometrial tissue. 5-Lipooxygenase (5-LOX) is often correlated with COX-I and COX-II. Thus,
      in addition to COX-I and COX-II, these are good candidate genes to study the effects of
      COX-II inhibitors on uterine cancers.

      Preliminary Data Since COX-II expression is seen in the endometrium and in other
      hormonally-dependent tumors, we have investigated the expression of COX-II in endometrial
      cancer. Our preliminary studies on 41 fixed samples of benign and neoplastic endometrium
      revealed that COX-II was not expressed in benign endometrial tissue, stains minimally (~1% of
      tumor cells) in well-differentiated endometrial carcinomas, and stains most strongly in
      poorly-differentiated carcinomas (~12% of tumor cells, most staining strongly). COX-II is
      expressed in all poorly differentiated uterine cancers. Our study also demonstrated that
      COX-II was also strongly expressed in uterine papillary serous carcinomas (UPSC) as well as
      clear cell carcinomas of the uterus. These findings were confirmed by Ferrandina, et al. A
      small percent of our patients as well as the patients in the Ferrandina study have only 1+ or
      1-5% staining. These 'low-expressers' only made up 1/13 (7.7%) of our patients.

      COX-II expression in endometrial carcinoma has a slight inverse correlation with apoptosis
      (r=-0.534). However, COX-II expression in endometrial carcinoma correlated with
      lymphovascular invasion (r=0.69) and depth of invasion (r=0.68). There was no correlation
      between COX-II expression and ER (r=0.03) or PR (r=-0.02). The presence of a
      poorly-differentiated tumor may imply a hormonally-independent pathway resulting in
      de-differentiation. In summary, our preliminary data reveals that COX-II expression is high
      in grade 2 and 3 endometrioid-type endometrial cancers, as well as UPSC and clear cell
      subtypes and is correlated with known clinical prognostic factors.

      Expression of COX-II has been identified in many types of human cancers. Uterine cancer is
      the most common gynecologic cancer in the US and there has been an increase in uterine cancer
      deaths over the past decade mainly due to the difficulty in treating recurrences in the more
      aggressive histologic types. The study co-investigators have also identified COX-II
      expression in grade 2 and 3 endometrioid-type, clear cell, and papillary serous types of
      uterine cancers. Upregulation of COX-II may control the cell cycle by regulating the
      proliferative capacity of neoplastic endometrial cells. This is a Phase II pre-post
      intervention comparison study in eligible patients looking at the effects of a COX-II
      inhibitor on uterine cancer. The patients whose endometrial biopsy shows grade 2 or 3
      endometrioid-type, clear cell, and papillary serous types of uterine cancers will be put on a
      selective COX-II inhibitor, Celebrex (Celecoxib) until the day of their surgery. The
      expression of COX-II and p21 will be quantified after treatment with Celecoxib in eligible
      patients. This expression will be evaluated by performing immunohistochemical staining on the
      endometrial biopsy (pre-intervention) and the hysterectomy specimen (post-intervention).
      Apoptosis, evaluated by the terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-
      digoxigenin nick end-labeling (TUNEL) assay, will also be evaluated and compared to COX-II
      expression in endometrial cancer in the two specimens, endometrial biopsy (pre-intervention)
      and uterus (post-intervention). In addition to IHC analysis and apoptosis, gene expression of
      COX-related genes in the post-intervention uterine specimens will. This gene expression will
      be compared to matched controls who were not treated with a COX-II inhibitor. COX-II
      expression will be correlated with established clinical prognostic factors including
      lymphovascular invasion, depth of myometrial invasion and lymph node involvement. We
      hypothesize that Celecoxib will downregulate the expression of COX-II in these tumor types as
      it does in other similar tumors. We also hypothesize that apoptosis, as measured with the
      TUNEL assay, will be increased in areas with less COX-II expression and should be inversely
      proportional to cellular p21 expression. Additionally, COX-II inhibitors affect apoptotic
      pathways even in cells that do not express COX-II. For low expressing cells, COX-II inhibitor
      activity may be better documented with apoptosis. We hypothesize COX-related gene expression
      will be altered thus suggesting an up- or down-regulation of these genes in the end-organ
      tissue. Documenting downregulation of COX-II enzyme and altered gene expression in
      endometrial carcinoma after treatment with Celecoxib may result in further prospective
      studies using selective COX-II inhibitors as effective, well-tolerated chemotherapeutic
      agents in these uterine cancers that are resistant to many current therapies.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to reported toxicity of Celecoxib at high doses
  </why_stopped>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">March 2004</completion_date>
  <primary_completion_date type="Actual">March 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare COX-II expression in grade 2 or grade 3 uterine cancers treated with Celecoxib, following endometrial biopsy (pre-intervention) and after hysterectomy (post-intervention)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>o To confirm the safety and tolerability of Celecoxib in this patient population.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>o To evaluate alterations in the cell cycle pre- and post-intervention with Celecoxib.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>o To evaluate apoptosis pre- and post-intervention using the TUNEL method.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>o To evaluate the relationship between COX-II expression, apoptosis, p21 with clinical prognostic factors.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>o To evaluate COX-related gene expression in the post-intervention uterine tissue by RT-PCR and compare to untreated matched controls.</measure>
  </secondary_outcome>
  <enrollment>23</enrollment>
  <condition>Uterine Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be at least 18 years of age

          -  Histologically confirmed uterine cancer of the following histologic types: grade 2 or
             grade 3 endometrioid-type, clear cell, or papillary serous types. The pre-therapy
             samples come from either an endometrial sampling (e.g. pipelle) or dilation and
             curettage of the uterus with or without hysteroscopy. Unstained slides of the primary
             tumor, a primary tumor block, or cytologic preparation must be available for review.
             COX-II expression is seen in the majority of patients with these tumor types. Effects
             of COX-II inhibitors occur even in the absence of COX-II expression and will be
             measured with other IHC staining, apoptosis studies and gene expression. Therefore,
             patients will not be tested for COX-II expression preoperatively in order to include
             them in the study.

          -  Disease status: Only patients with clinical stage I or stage II disease will be
             eligible.

          -  Negative urine pregnancy test in women of child-bearing potential (within 14 days of
             the initiation of Celebrex).

          -  All eligible patients need to have a Zubrod/ECOG/GOG performance status â‰¤2 that
             permits surgery, with or without staging, as indicated.

          -  All patients must be informed of the investigational nature of this study and must
             sign and give written informed consent in accordance with institutional and federal
             guidelines.

        Exclusion Criteria:

          -  Celecoxib is contraindicated in patients with known hypersensitivity to Celecoxib.
             Celecoxib should not be given to patients who have demonstrated allergic-type
             reactions to sulfonamides. Celecoxib should not be given to patients who have
             experienced asthma, urticaria, or allergic-type reactions after taking aspirin or
             other NSAIDs.

          -  Concurrent therapy: Patients who have had daily usage of any form of NSAID or aspirin
             prior to endometrial biopsy will be excluded from this study.

          -  Selective COX-II inhibitors have some activity on the gastrointestinal mucosa.
             Although Celecoxib is not contraindicated in patients with peptic ulcer disease, these
             patients will be excluded to avoid any untoward gastrointestinal side effects.

          -  There is no information regarding the use of Celecoxib in patients with advanced renal
             disease. Therefore, treatment with Celecoxib is not recommended in these patients.

          -  Patient has impairment of hepatic, renal or hematologic function as defined by the
             following baseline laboratory values performed &lt;= 4 weeks prior to the study:

               -  Serum SGOT and/or SGPT &gt; 2.5 times the institutional upper limit of normal
                  (IULN).

               -  Total serum bilirubin &gt; 1.5 mg/dL.

               -  History of chronic active hepatitis or cirrhosis.

               -  Serum creatinine &gt; 2.0 mg/dL.

               -  Platelets &lt; 100,000/mm3

               -  Absolute neutrophil count (ANC) &lt; 1500/mm3

               -  Hemoglobin &lt; 8.0 g/dL

               -  PT/PTT within normal range

               -  Pregnant or nursing women are excluded. Women of child-bearing potential must
                  agree to use a chemical or barrier contraceptive during the dosing portion of the
                  study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark H Einstein, M.D., M.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center and Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cao QJ, Einstein MH, Anderson PS, Runowicz CD, Balan R, Jones JG. Expression of COX-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas. Int J Gynecol Pathol. 2002 Apr;21(2):147-54.</citation>
    <PMID>11917224</PMID>
  </reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2005</study_first_submitted>
  <study_first_submitted_qc>September 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2005</study_first_posted>
  <last_update_submitted>April 22, 2012</last_update_submitted>
  <last_update_submitted_qc>April 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Mark H. Einstein</investigator_full_name>
    <investigator_title>Director, Clinical Research for Women's Health</investigator_title>
  </responsible_party>
  <keyword>Treatment</keyword>
  <keyword>Uterine Papillary Serous Carcinoma</keyword>
  <keyword>Clear Cell Carcinoma</keyword>
  <keyword>COX-2 Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

